This review highlights the potential of lipidomic and metabolomic biomarkers in predicting breast cancer prognosis and therapy response, enhancing patient care.
Illumina board agrees to spin off Grail rather than sell the cancer diagnostics firm
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS